Loading...
Market
How many EU countries will adopt HYMPAVZI™ into their health systems by 2025?
2
Resolution / Starting Odds
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
16+ countries • 25%
Official health policy announcements from EU countries
Story
European Commission Approves Pfizer’s HYMPAVZI™ for Severe Hemophilia A or B
Nov 20, 2024, 09:04 AM
The European Commission has approved Pfizer’s HYMPAVZI™ (marstacimab) for the treatment of adults and adolescents with severe hemophilia A or B without inhibitors. This approval marks a significant advancement in the treatment options available for hemophilia patients, providing a new once-weekly therapy. Pfizer announced that the approval will benefit eligible patients in the European Union, offering a new solution for managing this chronic condition.
View original story
Similar markets
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
Less than 5 • 25%
5 to 10 • 25%
11 to 15 • 25%
More than 15 • 25%
1-3 countries • 25%
4-6 countries • 25%
7-9 countries • 25%
10 or more countries • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
Less than 10 countries • 25%
10 to 20 countries • 25%
21 to 30 countries • 25%
More than 30 countries • 25%
Less than 5 countries • 25%
5 to 10 countries • 25%
11 to 20 countries • 25%
More than 20 countries • 25%